Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025R8" target="_blank" >RIV/61988987:17110/20:A21025R8 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/20:N0000085 RIV/00843989:_____/20:E0108432
Result on the web
<a href="https://link.springer.com/content/pdf/10.1007/s00277-020-03981-z.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s00277-020-03981-z.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00277-020-03981-z" target="_blank" >10.1007/s00277-020-03981-z</a>
Alternative languages
Result language
angličtina
Original language name
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Original language description
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status >= 2; median number of prior therapies was 1 (range 1-7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for >= 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3-4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ANNALS OF HEMATOLOGY
ISSN
0939-5555
e-ISSN
1432-0584
Volume of the periodical
99
Issue of the periodical within the volume
5
Country of publishing house
DE - GERMANY
Number of pages
12
Pages from-to
1049-1061
UT code for WoS article
000522712400001
EID of the result in the Scopus database
—